Murine versus human apolipoprotein E4: Differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models

Fan Liao  
*Washington University School of Medicine in St. Louis*

Tony J. Zhang  
*Washington University School of Medicine in St. Louis*

Hong Jiang  
*Washington University School of Medicine in St. Louis*

Katheryn B. Lefton  
*Washington University School of Medicine in St. Louis*

Grace O. Robinson  
*Washington University School of Medicine in St. Louis*

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Liao, Fan; Zhang, Tony J.; Jiang, Hong; Lefton, Katheryn B.; Robinson, Grace O.; Vassar, Robert; Sullivan, Patrick M.; and Holtman, David M., "Murine versus human apolipoprotein E4: Differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models." Acta Neuropathologica Communications. 3., 70. (2015).  
https://digitalcommons.wustl.edu/open_access_pubs/4385

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Fan Liao, Tony J. Zhang, Hong Jiang, Katheryn B. Lefton, Grace O. Robinson, Robert Vassar, Patrick M. Sullivan, and David M. Holtman
Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models

Fan Liao†, Tony J. Zhang†, Hong Jiang†, Katheryn B. Lefton1, Grace O. Robinson1, Robert Vassar2, Patrick M. Sullivan3,4 and David M. Holtzman1*

Abstract

Introduction: Amyloid β (Aβ) accumulates in the extracellular space as diffuse and neuritic plaques in Alzheimer’s disease (AD). Aβ also deposits on the walls of arterioles as cerebral amyloid angiopathy (CAA) in most cases of AD and sometimes independently of AD. Apolipoprotein E (apoE) ε4 is associated with increases in both Aβ plaques and CAA in humans. Studies in mouse models that develop Aβ deposition have shown that murine apoE and human apoE4 have different abilities to facilitate plaque or CAA formation when studied independently. To better understand and compare the effects of murine apoE and human apoE4, we bred 5XFAD (line 7031) transgenic mice so that they expressed one copy of murine apoE and one copy of human apoE4 under the control of the normal murine apoE regulatory elements (5XFAD/apoE\textsubscript{m}/4\textsubscript{m}).

Results: The 5XFAD/apoE\textsubscript{m}/4\textsubscript{m} mice contained levels of parenchymal CAA that were intermediate between 5XFAD/apoE\textsubscript{m}/m and 5XFAD/apoE\textsubscript{4}/4\textsubscript{m} mice. In 5XFAD/apoE\textsubscript{m}/4\textsubscript{m} mice, we found that Aβ parenchymal plaques co-localized with much more apoE than did parenchymal CAA, suggesting differential co-aggregation of apoE with Aβ in plaques versus CAA. More importantly, within the brain parenchyma of the 5XFAD/apoE\textsubscript{m}/4\textsubscript{m} mice, plaques contained more murine apoE, which on its own results in more pronounced and earlier plaque formation, while CAA contained more human apoE4 which on its own results in more pronounced CAA formation. We further confirmed the co-aggregation of mouse apoE with Aβ in plaques by showing a strong correlation between insoluble mouse apoE and insoluble Aβ in PS1APP-21/apoE\textsubscript{m}/4\textsubscript{m} mice which develop plaques without CAA.

Conclusions: These studies suggest that both murine apoE and human apoE4 facilitate differential opposing effects in influencing Aβ plaques versus CAA via different co-aggregation with these two amyloid lesions and set the stage for understanding these effects at a molecular level.

Keywords: Alzheimer’s disease, Apolipoprotein E, Amyloid plaques, Cerebral amyloid angiopathy

Introduction

The accumulation of amyloid β (Aβ) into plaques is one of the pathological hallmarks of Alzheimer’s disease (AD) [13]. The vast majority of patients diagnosed with AD also have cerebral amyloid angiopathy (CAA), deposition of Aβ on the cerebral vessels [16]. Some individuals develop CAA in the absence of AD [3]. CAA often associates with hemorrhagic lesions, ischemic lesions, encephalopathy, and dementia [39].

The strongest known genetic risk factor for late onset AD is the ε4 allele of apolipoprotein E (apoE), while the ε2 allele is protective [7, 8, 33]. Human apoE4 carriers have higher amyloid plaque load as well as greater amounts of CAA [12, 20, 29]. ApoE influences deposition of Aβ in plaques and CAA likely through some common mechanisms affecting Aβ clearance and aggregation. For example, apoE4 slows down Aβ clearance and leads to
This conflicting pattern suggests that apoE facilitates Aβ deposition in both lesions [2, 11, 15].

Out of 299 amino acids, human apoE4 shares only 70% homology with mouse apoE. Using APP transgenic (Tg) mice that develop Aβ deposition, it has been shown that mouse apoE is overall more amyloidogenic than any of the human apoE isoforms [9]. In addition, mouse apoE appears to be more prone to lead to parenchymal plaque formation while human apoE4 is more prone to lead to CAA formation in mice that generate wild type human Aβ peptide [10, 24]. This conflicting pattern suggests that apoE may affect plaques and CAA deposition via a different mechanism(s). This difference is not likely caused by differential overall Aβ clearance rates since a change in Aβ clearance and consequent concentration would probably have the same impact on both plaques and CAA. Another possibility is that this difference is mediated by differential co-aggregation of apoE with Aβ in parenchymal plaques or CAA. In this study, we asked whether mouse apoE vs human apoE4 differentially 1) lead to either parenchymal plaque formation versus CAA and 2) co-aggregate with Aβ in plaques and CAA by quantifying their degree of co-localization with plaques and CAA when they are expressed in the same brain at the same level.

Here we utilized APP Tg mice carrying one copy of endogenous mouse apoE and one copy of apoE4 (APP/apoE4/4). In this model, different apoE proteins interact with Aβ under an identical in vivo microenvironment. Therefore, the interactions between apoE and Aβ will depend on the intrinsic properties of each apoE isoform.

We first quantified the amyloid plaque and CAA load in 8-10 month old 5XFAD/apoE4/4, 5XFAD/apoE4/4 and 5XFAD/apoE4/4 mice and verified that apoE strongly facilitated amyloid deposition in CAA, and that mouse apoE facilitated parenchymal plaque deposition. We then assessed 5XFAD/apoE4/4 mice and found that in the presence of both mouse apoE and human apoE4, there was an intermediate level of CAA as compared to either 5XFAD/apoE4/4 or 5XFAD/apoE4/4 mice. In 5XFAD/apoE4/4 mice, mouse apoE co-localized with parenchymal plaques to a significantly greater extent while apoE4 co-localized with CAA to a significantly greater extent. Further, in 85 day old APPPS1-21/ apoE4/4 mice, which have plaques without CAA, insoluble Aβ was strongly correlated with insoluble mouse apoE but not apoE4. The data suggest that the type of apoE dictates whether apoE will lead to greater plaque versus CAA and that differences in apoE sequence and co-aggregation with plaques versus CAA likely leads to this difference. Understanding the molecular basis for this difference will lead to insights into disease pathogenesis that may have future treatment implications.

Materials and methods

Animals

5XFAD mice, line Tg7031 on a C57/B6SJL background (gift from Dr. Robert Vassar at Northwestern University) co-express the KM670/671NL, I716V, and V717I mutations in human APP (695), as well as the M146L and L286V mutations in human PS1 under control of the mouse Thy1 promoter [23]. APPPS1-21 mice on a C57BL/6 J background (gift from Dr. Mathias Jucker at Hertie-Institute for Clinical Brain Research) co-express human APP with a Swedish mutation (KM670/671NL) and mutant PS1 with the L166P mutation under the control of a Thy1 promoter [25]. ApoE4 knockin mice express apoE ε4 under control of the endogenous mouse regulatory elements on a C57BL/6 J background (apoEε4/4) [34]. 5XFAD mice carrying one copy (5XFAD/apoE4/4) or two copies (5XFAD/apoE4/4) of apoE4 were generated by breeding 5XFAD/apoE4/4 with apoE4/4 mice. APPPS1-21/apoE4/4 mice were generated by breeding APPPS1-21/apoE4/4 with apoEε4/4 mice. Age-matched non-APP/apoE4/4 mice were littermates of the corresponding APP mice. All experimental protocols were approved by the Animal Studies Committee at Washington University.

Tissue harvesting

The mice were perfused with ice cold PBS containing 0.3% heparin. One hemibrain was dissected and flash-frozen on dry ice and then stored at -80°C for biochemical assays. The other hemibrain was fixed in 4% paraformaldehyde for histological study. Before staining, serial coronal sections at 50 μm thickness were collected using a freezing sliding microtome (Leica).

X-34 staining

Quantitative analysis of fibrillar amyloid deposition was performed on 8-10 month old 5XFAD/apoE4/4, 5XFAD/apoE4/4 and 5XFAD/apoE4/4 mice as previously described [18]. Briefly, three sections per mouse (Bregma, -1.4 mm caudal to Bregma, -2.0 mm caudal to Bregma) were stained with X-34 and then scanned using a Nanozoomer slide scanner (Hamamatsu Photonics). Images were exported with NDP viewer (Hamamatsu Photonics), converted to grayscale, thresholded to highlight positive staining of plaques or CAA, and analyzed using ImageJ (National Institutes of Health). The average area covered by X-34 from the 3 sections/mouse was used to represent each mouse. The quantification was performed by an investigator who was blinded for the genotype of the animals.
Immunohistochemistry
Brain sections from 10-month-old 5XFAD/apoE<sup>m/4</sup> or 85-day-old APPPS1-21/apoE<sup>m/4</sup> mice were co-stained for fibrillar amyloid, mouse apoE, and apoE4 using X-34, anti-mouse apoE monoclonal antibody HJ6.3-Alexa Fluor 568 (generated in-house) and anti-human apoE monoclonal antibody HJ15.7-Alexa Fluor 488 (generated in-house), respectively. For quantification of apoE/CAA or apoE/plaque co-staining in 10-month-old 5XFAD/apoE<sup>m/4</sup> mice, brain sections were imaged using a Zeiss LSM 5 PASCAL system coupled to a Zeiss Axiocan 200 M confocal microscope. Three sections from each mouse were used and five fields containing CAA and five fields containing plaques on each section were imaged. Images were thresholded for corresponding colors and the degree of co-localization was analyzed with ImageJ. Percent area of CAA or plaque covered by mouse apoE or apoE4 was calculated and the average from 3 sections/mouse was used to represent each mouse. For quantification of apoE/plaques in 85-day-old APPPS1-21/apoE<sup>m/4</sup> mice, which were at the initiation of plaque deposition, all the plaques in the cortical area were counted under Nikon Eclipse 80i fluorescent microscope and the apoE co-staining status for each individual X-34 plaque was recorded. The average of 3 sections from each mouse was used to represent each mouse.

Tissue lysate ELISA
Brain cortices from 85-day-old APPPS1-21/apoE<sup>m/4</sup> and apoE<sup>m/4</sup> mice were sequentially homogenized with cold PBS, 1 % triton-X 100, and 5 M guanidine buffer in the presence of 1X protease inhibitor mixture (Roche). Aβ<sub>40</sub>, Aβ<sub>42</sub>, mouse apoE, and apoE4 in each fraction were measured by ELISA. For Aβ<sub>40</sub> or Aβ<sub>42</sub> ELISA, anti-Aβ<sub>35-40</sub> HJ2 (generated in-house) or anti-Aβ<sub>37-42</sub> HJ7.4 (generated in-house) was used as the capture antibody, and anti-Aβ<sub>13-28</sub> HJ15.1-biotin (generated in-house) as the detecting antibody [4]. For mouse apoE ELISA, plates were coated with HJ6.2 (in-house generated) at a concentration of 10 μg/ml in carbonate coating buffer at 4 °C overnight. After blocking with 2 % BSA in PBS at 37 °C for 1 h, the samples were loaded on the plates and incubated overnight at 4 °C. Then the plates were incubated in 300 ng/ml HJ6.8-biotin (generated in-house) at 37 °C for 1.5 h. Followed by a incubation in 1:10000 Streptavidin Poly-HRP40 Conjugate (Fitzgerald) at room temperature for 1.5 h, the plates were developed using Super Slow ELISA TMB (Sigma) and read on a Bio-Tek Synergy 2 plate reader at 650 nm. The standard curve was mouse apoE purified from mouse astrocytes conditioned medium using a polyclonal antibody (Calbiochem). Human apoE ELISA shared the same protocol as mouse apoE ELISA except for the antibodies were different. For human apoE ELISA, HJ15.6 (generated in-house) at a concentration of 10 μg/ml was used as the capture antibody and 150 ng/ml HJ15.4-biotin (generated in-house) was used as detecting antibody. Recombinant apoE4 (Leinco) was used as the standard for human apoE ELISA.

Data analysis
Statistical analyses were performed using GraphPad Prism (GraphPad Software, version 5.0). All data were analyzed using ANOVA, One-way ANOVA with repeated measures, student t-test or paired t-test as indicated in the respective figure legends. Sample sizes were specified in the respective figure legends. Data were expressed as mean ± S.E.M. unless otherwise specified.

Results
ApoE4 shifts parenchymal Aβ deposition from plaques to CAA in the 5XFAD mice
Plaque deposition begins in 5XFAD (line 7031) on mouse apoE background (5XFAD/apoE<sup>m/m</sup>) at the age of 4 months. When 5XFAD mice were bred onto an apoE4 background (5XFAD/apoE<sup>4/4</sup>), plaque deposition began at the age of 5 months (Additional file 1: Figure S1). To further determine the effect of replacing mouse apoE with apoE4 on Aβ plaques and CAA, we stained fibrillar amyloid with X-34 in 8-10 month old 5XFAD/apoE<sup>m/m</sup>, 5XFAD/apoE<sup>4/4</sup> and 5XFAD/apoE<sup>4/4</sup> mice (Fig. 1a). The amount of CAA on the blood vessels within the brain parenchyma (parenchymal CAA) and amyloid plaques were quantified. There is minimal parenchymal CAA compared to amyloid plaques in 5XFAD/apoE<sup>m/m</sup> animals (Fig. 1b, c). With the introduction of one copy of apoE4 (5XFAD/apoE<sup>m/4</sup>), the plaque load did not change while the CAA tended to increase (Fig. 1b, c). With two copies of apoE4 (5XFAD/apoE<sup>4/4</sup>), there was a significant reduction of plaque load (Fig. 1b) and a significant elevation of CAA (Fig. 1c) as compared to 5XFAD/apoE<sup>m/m</sup> mice.

Plaques contain more mouse apoE while parenchymal CAA contain more apoE4 in 5XFAD/apoE<sup>4/4</sup> mice
To determine whether the mouse apoE and apoE4 facilitate plaque or CAA differently via differential co-aggregation with Aβ in plaques and CAA, we examined the amount of apoE4 or mouse apoE co-localized with plaques and CAA. We co-stained amyloid deposition with an anti-mouse apoE specific antibody HJ6.3 (Additional file 2: Figure S2) and an anti-human apoE specific antibody HJ15.7 (Additional file 2: Figure S2) in 10-month-old 5XFAD/apoE<sup>4/4</sup> brains (Fig. 2). We first quantified co-localization of each form of apoE in relation to plaques and CAA. Within brain parenchyma, both apoE4 (3.33 ± 1.04 % in CAA vs 7.49 ± 0.71 % in plaques, n = 9, p < 0.05, paired t-test) and mouse apoE (1.23 ± 0.63 % in CAA vs 19.89 ± 1.30 % in plaques, n = 9, p < 0.001, paired t-test) exhibited less co-localization in parenchymal CAA as compared to plaques. However, the amount of each form
of apoE localized in the same lesion was different. Parenchymal plaques contained more mouse apoE immunoreactivity than apoE4 (Fig. 2a, b), whereas parenchymal CAA contained more apoE4 immunoreactivity than mouse apoE (Fig. 2d).

Next, we compared the co-localization of different apoE within parenchymal CAA (Fig. 2c) and the CAA on leptomeningeal vessels (leptomeningeal CAA, Fig. 3a). Interestingly, both mouse apoE (Fig. 3c) and apoE4 (Fig. 3d) exhibited significantly more co-localization with leptomeningeal CAA as compared to parenchymal CAA. In addition, while apoE4 co-localized more than mouse apoE within parenchymal CAA (Fig. 2d), leptomeningeal CAA co-localized with less apoE4 as compared to mouse apoE (Fig. 3b). For the mouse apoE to human apoE4 ratio, the ratios were similar in plaques and leptomeningeal CAA while parenchymal CAA had the lowest ratio (Additional file 3: Figure S3).

Mouse apoE and Aβ levels are highly correlated in plaques in APPPS1-21/apoE<sup>m/4</sup> cortices

To verify the differential co-aggregation of mouse vs. human apoE4 with Aβ plaques, we utilized another APP Tg mouse model, APPPS1-21. We first co-stained amyloid deposition with specific anti-mouse apoE antibody HJ6.3 and specific anti-human apoE antibody HJ15.7 in 85-day-old APPPS1-21/apoE<sup>m/4</sup> mice (Fig. 4). We found that CAA was absent in the APPPS1-21/apoE<sup>m/4</sup> cortex at this age, probably due to the low Aβ<sub>40</sub>/Aβ<sub>42</sub> ratio in the APPPS1-21 mouse model [25]. Interestingly, all (100 %) of the plaques contained mouse apoE (Fig. 4a, b); whereas only a very small percentage (1.67 ± 1.14 %) of plaques also contained apoE4 (Fig. 4a). There was no plaque that only contained apoE4.

To assess the level of mouse and human apoE in cortical tissue lysates of the same APPPS1-21/apoE<sup>m/4</sup> mice, we developed both a mouse and a human apoE...
specific ELISA (Additional file 4: Figure S4). We then performed a 3-step sequential extraction of APPPS1-21/apoE<sup>m/4</sup> cortex using PBS, 1 % Triton X-100 and 5 M guanidine, and measured apoE levels in these three fractions. Tissue from age-matched non-APP transgenic apoE<sup>m/4</sup> mice were also analyzed as controls to see the basal levels of apoE in the absence of amyloid plaques. In the non-APP transgenic, apoE<sup>m/4</sup> mice, we found that the mouse apoE and apoE<sub>4</sub> levels were similar in the sum of the three fractions (Fig. 5a). However, the fractional distributions of different apoE were very different. For mouse apoE, 50.9 ± 1.1 % was present in the PBS soluble fraction and only 4.7 ± 0.4 % was present in the insoluble (guanidine) fraction (Fig. 5b). ApoE<sub>4</sub> was more equally distributed in 3 fractions (Fig. 5b). The PBS soluble fraction contained significantly more (p < 0.001) mouse apoE than apoE<sub>4</sub> (Fig. 5a), while the insoluble fraction contained significantly more (p < 0.001) apoE<sub>4</sub> than mouse apoE (Fig. 5a).

In APPPS1-21/apoE<sup>m/4</sup> cortex which contained amyloid plaques, apoE<sub>4</sub> absolute levels (Fig. 5c) or fractional distribution (Fig. 5d) were unaltered as compared to that in apoE<sup>m/4</sup> cortices. For mouse apoE, the absolute levels were unaltered in the PBS and 1 % Triton fraction of APPPS1-21/apoE<sup>m/4</sup> cortices as compared to that in apoE<sup>m/4</sup>. However, the mouse apoE in the insoluble fraction of APPPS1-21/apoE<sup>m/4</sup> mice was significantly higher than that in apoE<sup>m/4</sup> mice (117.3 ± 21.7 vs 48.8 ± 4.4 ng/100 mg tissue for APPPS1-21/apoE<sup>m/4</sup> and apoE<sup>m/4</sup>, respectively; p < 0.01, Student t-test). As a result, the percentage of insoluble mouse apoE was increased in APPPS1-21/apoE<sup>m/4</sup> mice as compared to that in apoE<sup>m/4</sup> mice (10.0 ± 1.6 % vs 4.7 ± 0.4 % for APPPS1-21/apoE<sup>m/4</sup> and apoE<sup>m/4</sup>, respectively; p < 0.01, Student t-test; Fig. 5b, d). The increase of insoluble mouse apoE is very likely due to co-aggregation of mouse apoE with A<sub>β</sub> in the plaques, which did not occur to a significant extent with apoE<sub>4</sub>. To verify this possibility, we performed correlation analysis of

Fig. 2 Co-localization of mouse apoE and apoE<sub>4</sub> in CAA or plaques within the same brain parenchyma in SFAD/apoE<sup>m/4</sup> mice. 10-month-old SFAD/apoE<sup>m/4</sup> mice were co-stained with HJ6.3-Alexa 568 for mouse apoE, HJ15.7-Alexa 488 for apoE<sub>4</sub>, and X-34 for fibrillar amyloid. a b Representative images of co-staining for mouse apoE and apoE<sub>4</sub> in the plaques and % area of plaque covered by different apoE. c d Representative images of co-staining for mouse apoE and apoE<sub>4</sub> in parenchymal CAA and % area of parenchymal CAA covered by different apoE. Values connected by lines were measured from the same animals (n = 9/group; *p < 0.05, ***p < 0.001, paired t-test)
Fig. 3 Comparison between apoE co-localization in parenchymal and leptomeningeal CAA in the same 5XFAD/apoE<sup>m/4</sup> brains. Brain sections from 10 months old 5XFAD/apoE<sup>m/4</sup> animals were co-stained with HJ6.3-Alexa 568 for mouse apoE, HJ15.7-Alexa 488 for human apoE4, and X-34 for fibrillar amyloid. 

**a** Representative images of co-staining for mouse apoE and apoE4 in the leptomeningeal CAA and % area of leptomeningeal CAA covered by different apoE (n = 9/group). Scale bars, 50 μm. 

**b** % area of plaque, parenchymal and leptomeningeal CAA covered by mouse apoE. 

**c** % area of plaque, parenchymal and leptomeningeal CAA covered by human apoE4. Values connected by lines were measured from the same animals (n = 8/group; **p < 0.01, ***p < 0.001, One-way ANOVA repeated measures)

Fig. 4 Co-localization of mouse apoE and apoE4 in plaques within the same brain parenchyma in APPPS1-21/apoE<sup>m/4</sup> mice. Brain sections from 85-day-old APPPS1-21/apoE<sup>m/4</sup> animals (n = 7) were co-stained with HJ6.3-Alexa 568 for mouse apoE, HJ15.7-Alexa 488 for human apoE4, and X-34 for fibrillar amyloid. 

**a** Representative images and the % of plaques containing both mouse apoE and apoE4 (scale bar, 20 μm). 

**b** Representative images and the % of plaques containing only mouse apoE (scale bar, 20 μm)
insoluble Aβ and apoE levels in the same sample in the cortices of these APPPS1-21/apoE
m/4 mice. Mouse apoE demonstrated a strong correlation with insoluble Aβ42
(Fig. 5e), in agreement with the observation that mouse apoE highly co-localized with plaques by co-staining. In contrast, apoE4, which is poorly co-localized with plaques, demonstrated no correlation with Aβ42 (Fig. 5f). As expected, insoluble Aβ40 strongly correlated with insoluble Aβ42 in APPPS1-21/apoE
m/4 mice (Fig. 5g).

Discussion
APOE genotype is the strongest genetic risk factor for late-onset AD and CAA. ApoE4 is associated with increases in both plaque burden and CAA in humans relative to the other human apoE isoforms [17]. ApoE likely influences deposition of Aβ in plaques and CAA through some common mechanisms affecting Aβ clearance and aggregation. Interestingly, previous studies in mouse models of amyloid deposition have shown that murine apoE is significantly more amyloidogenic than human apoE isoforms, including apoE4 [9, 41]. Despite the fact that it is more amyloidogenic, previous studies showed that apoE4 led to greater CAA than mouse apoE. In the current study, we showed that mouse apoE and human apoE4 were each dominant when present in the same brain (Fig. 1): mouse apoE promoted plaques while apoE4 promoted CAA. Overall, these findings suggest that differences in the inherent properties/structures of each form interact with Aβ in different ways leading to differential co-aggregation of Aβ in parenchymal plaque versus CAA. In addition, we found that 5XFAD/apoE
m/4 have an intermediate level of CAA as compared to either 5XFAD/apoE
m/m or 5XFAD/apoE
4/4 mice. This is important as it is consistent with human data in which it has been found that apoE4, in a dose-dependent fashion, is associated with greater parenchymal CAA [22, 30, 42].

To investigate the co-aggregation of different apoE in plaques and CAA, we assessed co-localization of apoE and amyloid in these two lesions in the same brain. Our data clearly demonstrated that within the brain parenchyma, the degree to which apoE co-localizes with Aβ in plaques or CAA was associated with its ability to facilitate the corresponding lesion. Aβ plaques contained more mouse apoE which facilitates plaque deposition (Fig. 2b), while parenchymal CAA contained more apoE4 which facilitates the formation of parenchymal CAA (Fig. 2d).
addition, the fact that parenchymal plaques contained more apoE (regardless of whether it is mouse apoE or apoE4) also suggested that apoE interacted with Aβ in plaques and CAA differently.

While most apoE present in physiological fluids such as CSF may not complex with monomeric Aβ [36], there is no question that once Aβ aggregates in the brain parenchyma or in CAA in the form of fibrils, apoE is then found co-aggregated with amyloid. However, data quantifying the amount of individual apoE isoforms co-depositing with Aβ in plaques or CAA are lacking. Although in PDAPP/apoE4/4 mice, the co-localization of apoE with Aβ plaques was higher than that in PDAPP/apoE3/3 and PDAPP/apoE2/2 mice [1], the different Aβ concentration and oligomerization states in individual mice with different apoE genotypes could influence the results. In the current study, the co-localization of different forms of apoE with different amyloid lesions within brain parenchyma was compared in the same mice carrying one copy of each apoE isoform and expressing each copy under the same regulatory elements at the same level (5XFAD/apoE3/4). Thus, the Aβ environment was identical for both apoE isoforms and the data provided definitive in vivo confirmation that mouse apoE and human apoE4 differentially facilitate specific types of amyloid deposition at least in part by co-aggregating with them differentially. The different % area covered by mouse apoE vs. human apoE4 observed here is likely not an artifact caused by the performance of apoE antibodies since plaques co-localized more with mouse apoE while parenchymal CAA co-localized more with apoE4. Furthermore, this co-localization of apoE and Aβ in plaques was verified by correlating Aβ with different apoE in the insoluble fraction of APPPS1-21/apoE3/4 mice. Interestingly, while our current data and previous studies using APP transgenic mice generating normal human Aβ [10, 24] suggested that apoE4 redistributed Aβ deposition to CAA as compared to mouse apoE, a previous study using mice expressing human Dutch/Iowa (E22Q/D23N) mutant Aβ showed an opposite pattern [38]. In transgenic mice (Tg-SwDI) that accumulate human Dutch/Iowa (E22Q/D23N) mutant Aβ, both human apoE3 and apoE4 strongly shifted the Aβ deposition from CAA into plaques [38]. Unlike in general AD populations where apoE4 is strongly associated with increased plaques and CAA, in humans with the rare Dutch mutation, apoE4 genotype was not correlated with plaques or CAA [5]. The Dutch mutation resides within amino acids 12-28 of Aβ peptide, a domain which appears to be required for interaction with apoE [33]. Taken together, our data and previous studies suggested that apoE modifies Aβ pathology through interaction with Aβ aggregates.

Since mouse apoE and apoE4 in 5XFAD/apoE3/4 brains were exposed to identical Aβ conditions, the co-aggregation of different apoE with Aβ in plaques or CAA was determined by the intrinsic properties of different apoE such as their binding preference to a certain species of Aβ or their concentration. CAA contains a higher Aβ40/Aβ42 ratio than do plaques [14] although Aβ42 is required to “seed” CAA [19]. The observation that apoE4 better co-localized with parenchymal CAA than plaques was not likely due to its higher binding preference to Aβ40 over Aβ42. If this were the case, we should expect to see even more apoE4 present than mouse apoE in the leptomeningeal CAA since the ratio of Aβ40/Aβ42 is even higher in leptomeningeal CAA than that in parenchymal CAA [26]. However in leptomeningeal CAA, we observed less apoE4 than mouse apoE. To see whether apoE levels play a role in the different co-aggregation, we measured apoE levels in cortical lysates of apoE3/4 and APPPS1-21/apoE3/4 mice. The total levels of mouse apoE and apoE4 in brain lysates were similar (Fig. 5) in apoE3/4 mice but their fractional distribution was different. In general there was more mouse apoE in the PBS soluble fraction while there was more human apoE4 in the insoluble fraction in the non-APP/apoE3/4 mice. This suggests an inherent difference in the biochemical properties of mouse apoE vs. human apoE4. It is possible that the conformation of mouse apoE in the PBS soluble fraction localized in parenchyma in such a way to interact with Aβ seeds that forms plaques as compared to apoE4 resulting in its precipitation into plaques to a greater extent. It is also possible that the structure of apoE4 may result in its localization to a greater extent in the vasculature, enabling it to interact to a greater extent with Aβ seeds that form CAA.

When leptomeningeal CAA and parenchymal CAA were compared, we found that 1) leptomeningeal CAA contained much higher apoE than did parenchymal CAA, and 2) leptomeningeal CAA contained more mouse apoE while parenchymal CAA contained more apoE4. These observations suggested that apoE might be differently involved during the formation of CAA in blood vessels of different locations.

**Conclusion**

Understanding how apoE influences the development of parenchymal plaques versus CAA is important. While this study does not provide the molecular basis for why mouse apoE and human apoE4 result in differential plaques versus CAA, it demonstrates that apoE is a major determinant of where Aβ deposits given that the Aβ in the in vivo microenvironment is the same. Therefore, studying the differences in sequence (30 % difference in sequence) and structure between mouse and human apoE that result in these differences could provide important insights. For example, understanding the structural variations could provide new insight into how to block or influence the apoE/Aβ interaction. In addition, treatment with some anti-Aβ antibodies has resulted in humans in the
complication of amyloid-related imaging abnormalities either with edema or hemorrhage. This complication is far more frequent in apoE positive individuals [31, 32]. It was also observed that Aβ immunotherapy was associated with redistribution of apoE from cortical plaques to cerebral vessel walls, mirroring the altered distribution of Aβ [28]. Understanding the basis for the differential effects of apoE on plaques vs. CAA might provide important insights into this phenomenon that could lead to ways to understand and prevent it.

Additional files

Additional file 1: Figure S1. Aβ plaque onset age in 5XFAD/apoE<sup>−/−</sup> and 5XFAD/apoE<sup>4/4</sup> brain. Aβ immunostaining was performed using biotinylated anti-Aβ<sub>1-11</sub> monoclonal antibody HJ3.4B. a Brain section from 4 month old 5XFAD/apoE<sup>−/−</sup> mouse. b Brain section from 4 month old 5XFAD/apoE<sup>4/4</sup> mouse. Scale bar, 1 mm. Plaques are indicated by arrows. (TIF 2146 kb)

Additional file 2: Figure S2. Specific antibodies for mouse apoE and human apoE4 immunostaining. 5XFAD/apoE<sup>−/−</sup> and 5XFAD/apoE<sup>4/4</sup> brain sections were immunostained with HJ6.3B for mouse apoE and HJ15.7B for human apoE4 (scale bar, 400 μm). (TIF 1678 kb)

Additional file 3: Figure S3. The ratio of mouse apoE to human apoE4 within different amyloid lesions in 10 month old 5XFAD/apoE<sup>−/−</sup> brains shown in Fig. 2 and Fig. 3 (n = 8/group, **, p < 0.001; One-way ANOVA repeated measures). (TIF 174 kb)

Additional file 4: Figure S4. Specific ELISA for mouse apoE and human apoE. a Mouse apoE was detected using HJ6.2 as the capture antibody and HJ6.6B-biotin as the detecting antibody. b Human apoE was detected using HJ15.6 as the capture antibody and HJ15.4-biotin as the detecting antibody. (TIF 372 kb)

Competing interests

D. M. H. cofounded and is on the scientific advisory board of C2N Diagnostics. D. M. H. consults for Genentech, AstraZeneca, Neurophage, AbbVie and Denali. Washington University receives grants that support laboratory research of D. M. H. from Eli Lilly and C2N Diagnostics.

Authors’ contribution

FL designed the study, performed experiments, analyzed the data and wrote the manuscript. TJZ performed experiments, analyzed the data and wrote the manuscript. HI performed experiments. KBL performed experiments. GOR performed experiments. RV provided the 5XFAD (line 7031) mouse and performed experiments. RP provided the 5XFAD<sup>−/−</sup> brains and discussed the data. PMIS provided the apoE<sup>−/−</sup> KI mice and discussed the data. DHM designed the study, analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work is supported by BrightFocus Foundation Grant A20130337F (FL), NIH R01AG047644 (DMH), NIH S10 RR0227552 (Shared Instrumentation Grant).

Author details

1Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA. 2Department of Cell and Molecular Biology, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. 3GRECC, Durham Veterans Affairs Medical Center, Durham, NC 27710, USA. 4Department of Medicine (Geriatrics), Duke University Medical Center, Durham, NC 27710, USA.

Received: 2 November 2015 Accepted: 2 November 2015 Published online: 10 November 2015

References

1. Bales KR, Liu F, Wu S, Lin S, Koger D, Delong C, et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci. 2009;29:6771–9. doi:10.1523/JNEUROSCI.0887-09.2009.
2. Bales KR, Verina T, Dodel RC, Du Y, Abliszl L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263–4. doi:10.1038/11971-263.
3. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol. 2009;118:103–13. doi:10.1007/s00702-009-0522-3.
4. Bero AW, Yan P, Roh JH, Cinitti JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750–6. doi:10.1038/nrn3081.
5. Bornebroek M, Haan J, Van Duinen SG, Maat-Schieman ML, Van Buchem MA, Bakker E, et al. Dutch hereditary cerebral amyloid angiopathy: structural lesions and apolipoprotein E genotype. Ann Neurol. 1997;41:695–8. doi:10.1002/ana.410410523.
6. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med. 2013;5:189ra57. doi:10.1126/scitranslmed.3001556.
7. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmeichel DE, Gaskell PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180–4. doi:10.1038/ng0694-180.
8. Corder EH, Saunders AM, Strittmatter WJ, Schmeichel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1995;261:921–3.
9. Fagan AM, Watson M, Parsadimian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2009;32:305–18. doi:10.1016/j.nbd.2002.05.036.
10. Fryer JD, Simons K, Parsadimian M, Bales KR, Paul SM, Sullivan PM, et al. Human apolipoprotein E4 alters the amyloid-beta 40/42 ratio and promotes the formation of cerebral amyloid angiopathy in an apolipoprotein E transgenic model. J Neurosci. 2005;25:2803–10. doi:10.1523/JNEUROCIR.3170.2004.
11. Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadimian M, et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci. 2003;23:7889–96.
12. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT, Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254–9. doi:10.1002/ana.410380219.
13. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6. doi:10.1126/science.1072994.
14. Herzig MC, Winker DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. ApoE is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004;7:754–60. doi:10.1038/nn1302.
15. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model. Ann Neurol. 2000;47:379–47.
16. Jellinger KA. Alzheimer disease and cerebrovascular pathologic pathology: an update. J Neural Transm (Vienna). 2002;109:813–6. doi:10.1075/jn.109(2002)056.
17. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron. 2009;63:287–303. doi:10.1016/j.neuron.2009.06.026.
18. Kim J, Etoroa AE, Jiang H, Liao F, Verghese PB, Kim J, et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβeta amyloidosis. J Exp Med. 2012;209:249–56. doi:10.1084/jem.20121274.
19. McGowan E, Pickford F, Kim J, Orntleed L, Eriksen J, Yu C, et al. Abeta<sub>42</sub> is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2007;54:191–9. doi:10.1016/j.neuron.2005.06.030.
20. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122–31. doi:10.1002/ana.21843.
21. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163–6.
22. Nelson PT, Pious NM, Jicha GA, Wilcock DM, Farooq DW, Estus S, et al. APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid
accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72:708–15. doi:10.1097/NEN.0b013e318292c5b9.

23. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129–40. doi:10.1523/JNEUROSCI.1302-06.2006.

24. Oddo S, Caccamo A, Cheng D, LaFeLFA FM. Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol. 2009;19:421–30. doi:10.1111/j.1750-3639.2008.00194.x.

25. Radde R, Bolmont T, Kaeser SA, Coomansawamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940–6. doi:10.1038/sj.embor.7400784.

26. Roher AE, Kuo YM, Esh C, Knobel C, Weiss N, Kalbback W, et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med. 2003;9:112–22.

27. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartenman D, et al. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:18767–72. doi:10.1073/pnas.0604011103.

28. Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S, et al. Abeta immunotherapy for Alzheimer's disease effects on apoE and cerebral vasculopathy. Acta Neuropathol. 2014;128:777–89. doi:10.1007/s00401-014-1340-9.

29. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:649–53.

30. Serrano-Pozo A, Giallonsi SE, Blacker D, Gomez-Isla T, Beyenwosy RA, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol. 2014;75:597–601. doi:10.1002/ana.24125.

31. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakcs J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241–9. doi:10.1016/S1474-4422(12)70015-7.

32. Sperling RA, Jack Jr CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimer's Dement. 2011;7:367–85. doi:10.1016/j.jalz.2011.05.2351.

33. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Englund J, Selvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977–81.

34. Sullivan PM, Mezduur H, Aratani Y, Knebel C, Weiss N, Kalbback W, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and arterosclerosis. J Biol Chem. 1997;272:17972–80.

35. Thal DR, Papassotiropoulos A, Saito TC, Griffin WS, Mrak RE, Kolsch H, et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol. 2010;120:169–83. doi:10.1007/s00401-010-0707-9.

36. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110:E1807–16. doi:10.1073/pnas.1220484110.

37. Wisniewski T, Framjione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992;135:235–8.

38. Xu F, Vitek MP, Colton CA, Previti ML, Ghahreholonarehe N, Davis J, et al. Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. J Neurosci. 2008;28:5312–20. doi:10.1523/JNEUROSCI.1042-08.2008.

39. Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke. 2015;17:17–30. doi:10.5853/jos.2015.17.1.17.

40. Yang J, Ji Y, Mehta P, Bates KA, Sun T, Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in Tg-SwDI mice. J Alzheimers Dis. 2011;24:269–85. doi:10.3233/JAD-2011-101401.